Keywords: Hikma Pharma, First-half 2011 financial results
Jordan’s Hikma delivers 10.4% sales growth in first half 2011
Article | 25 August 2011
Jordon-headquartered Hikma Pharmaceuticals (LSE: HIK) has reported interim results for the six months ended June 30, 2011, showing that group revenue increased ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
